NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma
ConditionCutaneous Melanoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAC Camargo Cancer Center
About this trial
This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma.
Patients are included after receiving treatment as part of routine clinical practice. Decisions about treatment, including whether to start anti-PD1 therapy before surgery, are made by the treating physician and are not influenced by the study.
The study compares outcomes between patients who started anti-PD1 therapy before surgery and those treated according to the usual timing in clinical practice.
No treatments are assigned as part of the study.
Eligibility criteria
Qualifiers
None
Disqualifiers
Patients without sufficient clinical or follow-up data.
Patients who do not provide informed consent (for prospective cohort).
Trial design
Treatments tested in this trial
- Anti-PD1 Therapy Timing
Treatment groups
250 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov